Risperdal, Seroquel sNDAs Submitted For Acute Mania; Other sNDAs Filed
This article was originally published in Pharmaceutical Approvals Monthly
AstraZeneca and Johnson & Johnson are both pursuing acute mania indications for their atypical antipsychotic agents via supplemental NDAs submitted in December.
You may also be interested in...
GlaxoSmithKline is discussing the scope of a bipolar indication for Lamictal following an April 4 "approvable" letter for the new claim.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011